Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...

Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and ...

Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.

including those with and without ESR1 mutations or PI3K-pathway mutations and including those previously treated with a CDK4/6 inhibitor. "The consistency of these results across clinically ...

including patients who received prior treatment with CDK4/6 inhibitors, and those with PI3K pathway mutations. Interim overall survival (OS) analyses at 31% maturity in patients with ESR1 ...